Organization
University of California, San Francisco, Division of Endocrinology, San Francisco, CA
27 abstracts
Abstract
Bridging therapies used in trials testing CAR-T therapies.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Drexel University College of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Correlating survival outcomes in patients with advanced prostate cancer with novel hyperpolarized 13C MRI metabolic imaging biomarkers.Org: Radiology and Biomedical Imaging, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Helen Diller Family Comprehensive Cancer Center,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.Org: Department of Surgery, University of California, San Francisco, San Francisco, CA, Department of Medicine, University of California, San Francisco, San Francisco, CA, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Weill Cornell Medicine Department of Population Health Sciences, New York, NY, University of California, San Francisco Department of Surgery, San Francisco, CA,
Abstract
Quality and accessibility of liquid biopsy information: An analysis of online content.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Dana-Farber Cancer Institute, Harvard Medical School, University of California San Francisco,
Abstract
Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.Org: University of California San Francisco, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Dana-Farber/Brigham and Women's Cancer Center, San Francisco VA Medical Center, University of Florida Health Shands Hospital,
Abstract
Natural language processing identification of documented mental health symptoms associated with risk of mental health disorders in patients with cancer.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California Comprehensive Cancer Center,
Abstract
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.Org: Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Detection of early-stage cancers using circulating orphan non-coding RNAs in blood.Org: Exai Bio Inc., Renown Health-Pennington Cancer Institute, University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.Org: Dana-Farber Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, University Hospital and University of Zurich,
Abstract
Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419).Org: University Hospital and University of Zurich, Institute of Neuropathology, University Hospital Düsseldorf, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University and City of Health and Science Hospital,
Abstract
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.Org: UCLA Ahmanson Translational Theranostics Division, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UCLA Nuclear Medicine, Department of Radiology and Biomedical Imaging, University of California Irvine,
Abstract
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UT Southwestern Medical Center, Hôpital Pitié-Salpêtrière, NYU Department of Urology, Perlmutter Cancer Center, New York University Langone Health,
Abstract
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, MD Anderson Cancer Center, Moffitt Cancer Center and Research Institute, Nebraska Cancer Specialists,
Abstract
The cognitive load of inpatient consults involving immune-related adverse events.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco,
Abstract
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, New York University Langone Health, New York, NY, Seagen, Inc.,
Abstract
Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Ohio State University Wexner Medical Center, University of Rochester Medical Center,
Abstract
Consensus molecular subtypes and orphan non-coding RNAs in colorectal cancer.Org: Exai Bio Inc., City of Hope Comprehensive Cancer Center/AccessHope, University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,
Abstract
Receipt of financial drug assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer (NSCLC).Org: UCSF School of Medicine, University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
Patient expectations and understanding of treatment intent in Belize.Org: Stanford Hospital & Clinics, University of Rochester School of Medicine & Dentistry, UCSF School of Medicine, Karl Heusner Memorial Hospital, University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
Cost of breast cancer screening in the USA: Comparison of current practice, advocated guidelines, and a personalized risk-based approach.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, OptumLabs at UnitedHealth Group, UCSF Helen Diller Family Comprehensive Cancer Center, Karolinska Institutet, Optum Labs,
Abstract
External validation of biomechanical computed tomography for fracture risk classification in metastatic hormone sensitive prostate cancer.Org: MD Anderson Cancer Center, University of Pennsylvania School of Medicine, University of Pennsylvania, O.N. Diagnostics, University of California, Berkeley,
Abstract
A20 AND PROTECTION FROM SYSTEMIC LUPUS ERYTHEMATOSUS AND ARTHRITIS Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
A RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL OF ETORICOXIB AND INDOMETHACIN IN THE TREATMENT OF ACUTE GOUTY ARTHRITISOrg: Merck & Co., Inc., University of Pennsylvania School of Medicine, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Centro de Osteopatias, Reumatologia e Investigaciones Clinicas, Unidad Medica Torre Plaza,